Roles of circular RNAs in the pathogenesis and treatment of pancreatic cancer

Seimiya, Takahiro; Otsuka, Motoyuki; Fujishiro, Mitsuhiro

doi:10.3389/fcell.2022.1023332

Cited by 5 publications

(5 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CircRNA typically consists of 100 to 4000 base pairs in length. Instead of a linear shape formed by lncRNA and miRNA, it forms a covalently closed loop structure that links 5 ′ and 3 ′ ends [97]. This unique structure, which lacks free ends, enhances stability and resistance to degradation by RNase R, a 3 ′ to 5 ′ exoribonuclease.…”

Section: Circular Rna (Circrna)mentioning

confidence: 99%

“…This unique structure, which lacks free ends, enhances stability and resistance to degradation by RNase R, a 3 ′ to 5 ′ exoribonuclease. Additionally, circRNA is ubiquitously expressed in body fluids such as plasma, saliva, and urine, making it an excellent biomarker for cancer diagnosis [97]. A meta-analysis including six diagnostic studies suggested that circRNA could distinguish PDAC patients from healthy groups, with relatively high AUC, sensitivity, and specificity values of 0.86, 84%, and 80%, respectively [98].…”

Section: Circular Rna (Circrna)mentioning

confidence: 99%

See 1 more Smart Citation

Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer

Gu,

Minko

2024

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers, presents significant challenges in diagnosis and treatment due to its aggressive, metastatic nature and lack of early detection methods. A key obstacle in PDAC treatment is the highly complex tumor environment characterized by dense stroma surrounding the tumor, which hinders effective drug delivery. Nanotechnology can offer innovative solutions to these challenges, particularly in creating novel drug delivery systems for existing anticancer drugs for PDAC, such as gemcitabine and paclitaxel. By using customization methods such as incorporating conjugated targeting ligands, tumor-penetrating peptides, and therapeutic nucleic acids, these nanoparticle-based systems enhance drug solubility, extend circulation time, improve tumor targeting, and control drug release, thereby minimizing side effects and toxicity in healthy tissues. Moreover, nanoparticles have also shown potential in precise diagnostic methods for PDAC. This literature review will delve into targeted mechanisms, pathways, and approaches in treating pancreatic cancer. Additional emphasis is placed on the study of nanoparticle-based delivery systems, with a brief mention of those in clinical trials. Overall, the overview illustrates the significant advances in nanomedicine, underscoring its role in transcending the constraints of conventional PDAC therapies and diagnostics.

show abstract

Section: Circular Rna (Circrna)mentioning

confidence: 99%

Section: Circular Rna (Circrna)mentioning

confidence: 99%

Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer

Gu,

Minko

2024

Cancers

View full text Add to dashboard Cite

show abstract

“…(3) Acting as scaffolds for protein complexes leading to mRNA-protein complex formation enhancing mRNA expression and tumour progression. So, they will be a target for different therapies of PC soon (Figure 2) [7,8].…”

Section: Genetics Molecular Alterations Metabolic Changes and Cancer ...mentioning

confidence: 99%

“…The 5-year survival rate after PC diagnosis may reach only 5-11%. However, for the very early diagnosed ones, it may rise to 85% and horribly; for the locally advanced or the metastatic ones, it may become less than 3% [1,8,16,37]. For a better outcome of this catastrophic tumour, it should be diagnosed early and treated through multidisciplinary teams of surgeons, gastroenterologists/interventional upper endoscopists, medical/radiation oncologists, diagnostic/intervention [16].…”

Section: Treatment Of Pdacmentioning

confidence: 99%

Pancreatic Cancer: Updates in Pathogenesis and Therapies

Hamdy Gad

2023

Pancreatic Cancer- Updates in Pathogenesis, Diagnosis and Therapies

View full text Add to dashboard Cite

Despite the progress in pancreatic cancer (PC) chemo/radiotherapies, immunotherapies, and novel targeted therapies and the improvement in its peri-operative management policies, it still has a dismal catastrophic prognosis due to delayed detection, early neural and vascular invasions, early micro-metastatic spread, tumour heterogeneities, drug resistance either intrinsic or acquired, unique desmoplastic stroma, and tumour microenvironment (TME). Understanding tumour pathogenesis at the detailed genetic/epigenetic/metabolic/molecular levels as well as studying the tumour risk factors and its known precancerous lesions aggressively is required for getting a more successful therapy for this challenging tumour. For a better outcome of this catastrophic tumour, it should be diagnosed early and treated through multidisciplinary teams of surgeons, gastroenterologists/interventional upper endoscopists, medical/radiation oncologists, diagnostic/intervention radiologists, and pathologists at high-volume centres. Moreover, surgical resection with a negative margin (R0) is the only cure for it. In this chapter; we discuss the recently updated knowledge of PC pathogenesis, risk factors, and precancerous lesions as well as its different management tools (i.e. surgery, chemo/radiotherapies, immunotherapies, novel targeted therapies, local ablative therapies, etc.).

show abstract

“…They play crucial post-transcriptional regulatory roles in the pathogenesis of various diseases, particularly cancers. 16 – 19 There is a growing consensus suggesting that circRNAs also have crucial regulatory functions in DR development and could serve as potential markers for diagnosing and treating DR. 20 – 22 Several circRNAs, such as CircDNMT3B, cZNF609, and CircHIPK3, have been implicated in retinal vascular dysfunction in a diabetic environment. 21 In a previous research, we documented hsa_circ_0001953 is upregulated in cases of proliferative DR (PDR) and has huge prospects for early diagnosis of this disease.…”

Section: Introductionmentioning

confidence: 99%

Role of Hsa_circ_0000880 in the Regulation of High Glucose-Induced Apoptosis of Retinal Microvascular Endothelial Cells

Wang,

Yang,

et al. 2024

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose Circular RNAs (circRNAs) have been verified to participate in multiple biological processes and disease progression. Yet, the role of circRNAs in the pathogenesis of diabetic retinopathy (DR) is still poorly understood and deserves further study. This study aimed to investigate the role of circRNAs in the regulation of high glucose (HG)-induced apoptosis of retinal microvascular endothelial cells (RMECs). Methods Epiretinal membranes from patients with DR and nondiabetic patients with idiopathic macular epiretinal membrane were collected for this study. The circRNA microarrays were performed using high-throughput sequencing. Hierarchical clustering, functional enrichment, and network regulation analyses were used to analyze the data generated by high-throughput sequencing. Next, RMECs were subjected to HG (25 mM) conditions to induce RMECs apoptosis in vitro. A series of experiments, such as Transwell, the Scratch wound, and tube formation, were conducted to explore the regulatory effect of circRNA on RMECs. Fluorescence in situ hybridization (FISH), immunofluorescence staining, and Western blot were used to study the mechanism underlying circRNA-mediated regulation. Results A total of 53 differentially expressed circRNAs were found in patients with DR. Among these, hsa_circ_0000880 was significantly upregulated in both the diabetic epiretinal membranes and in an in vitro DR model of HG-treated RMECs. Hsa_circ_0000880 knockout facilitated RMECs vitality and decreased the paracellular permeability of RMECs under hyperglycemia. More importantly, silencing of hsa_circ_0000880 significantly inhibited HG-induced ROS production and RMECs apoptosis. Hsa_circ_0000880 acted as an endogenous sponge for eukaryotic initiation factor 4A-III (EIF4A3). Knockout of hsa_circ_0000880 reversed HG-induced decrease in EIF4A3 protein level. Conclusions Our findings suggest that hsa_circ_0000880 is a novel circRNA can induce RMECs apoptosis in response to HG conditions by sponging EIF4A3, offering an innovative treatment approach against DR. Translational Relevance The circRNAs participate in the dysregulation of microvascular endothelial function induced by HG conditions, indicating a promising therapeutic target for DR.

show abstract

Roles of circular RNAs in the pathogenesis and treatment of pancreatic cancer

Cited by 5 publications

References 96 publications

Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer

Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer

Pancreatic Cancer: Updates in Pathogenesis and Therapies

Role of Hsa_circ_0000880 in the Regulation of High Glucose-Induced Apoptosis of Retinal Microvascular Endothelial Cells

Contact Info

Product

Resources

About